Work

Phase II trial of abiraterone acetate (AA) treatment for metastatic prostate cancer (PC) patients with a PSA of more than four following initial androgen deprivation therapy: SWOG S1014.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.7_suppl.152

Authors: Thomas W. Flaig, Catherine M. Tangen, Maha Hussain, Neeraj Agarwal, Nicholas Mitsiades, Hari Anant Deshpande, Ulka N. Vaishampayan, Ian Murchie Thompson

Institutions: University of Colorado Cancer Center, Fred Hutch Cancer Center, U-M Rogel Cancer Center, Huntsman Cancer Institute, Baylor College of Medicine, Yale Cancer Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, The University of Texas at San Antonio Health Science Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2591459283

Cites:

Cited by: 2

Related to: 10